2 completed, 1 terminated. 3 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 3 | Completed 2, Terminated 1 |
Follow Hyperargininemia: new trials by email Literature Review of Hyperargininemia trials Research Report on Hyperargininemia
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Pegzilarginase in Subjects <24 Months Old With Arginase 1 Deficiency Pegzilarginase - Arginase 1 Deficiency | Phase 3 | Completed | Immedica Pharma AB | 3 | 2024-08-30 | 2026-05-22 |
| A Study of Safety of Weekly Subcutaneous Pegzilarginase in Subjects With Arginase 1 Deficiency Pegzilarginase - Arginase I Deficiency, Hyperargininemia | Phase 3 | Terminated | Aeglea Biotherapeutics | 3 | 2023-04-04 | 2023-07-27 |
| Efficacy and Safety of Pegzilarginase in Patients With Arginase 1 Deficiency Pegzilarginase, Placebo - Arginase I Deficiency, Hyperargininemia | Phase 3 | Completed | Immedica Pharma AB | 32 | 2019-05-01 | 2026-08-21 |
Amino Acid Metabolism, Inborn Errors (3) · Brain Diseases (3) · Brain Diseases, Metabolic (3) · Brain Diseases, Metabolic, Inborn (3) · Central Nervous System Diseases (3) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (3) · Genetic Diseases, Inborn (3) · Metabolic Diseases (3) · Metabolism, Inborn Errors (3) · Nervous System Diseases (3) · Nutritional and Metabolic Diseases (3) · Urea Cycle Disorders, Inborn (3)
Immedica Pharma AB (2) · Aeglea Biotherapeutics (1)
Austria (2) · Canada (2) · United Kingdom (2) · France (1) · Germany (1) · Italy (1) · Portugal (1) · United States (1)
Mattias Rudebeck, PhD MSc BMedSc (2) · Cortney Caudill (1)